Stockscreener 앱 받기
0.6968
1.56%
0.0107
전일 마감가:
$0.6861
열려 있는:
$0.69
하루 거래량:
373.46K
Relative Volume:
2.96
시가총액:
$67.06M
수익:
$775.30K
순이익/손실:
$-35.32M
주가수익비율:
-1.2443
EPS:
-0.56
순현금흐름:
$-19.15M
1주 성능:
-13.98%
1개월 성능:
+0.21%
6개월 성능:
-4.23%
1년 성능:
-9.27%
1일 변동 폭
$0.62
$0.73
1주일 범위
$0.62
$0.84
52주 변동 폭
$0.4301
$1.23
VolitionRX Ltd Stock (VNRX) Company Profile
명칭
VolitionRX Ltd
전화
646 650 1351
주소
No. 24-05 Shaw Centre, 1 Scotts Road, Singapore, TX
VNRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VNRX
VolitionRX Ltd
|
0.6968 | 67.06M | 775.30K | -35.32M | -19.15M | -0.56 |
|
TMO
Thermo Fisher Scientific Inc
|
521.66 | 199.82B | 42.37B | 6.14B | 7.78B | 15.26 |
|
DHR
Danaher Corp
|
238.83 | 173.66B | 23.74B | 3.89B | 4.98B | 7.93 |
|
A
Agilent Technologies Inc
|
138.14 | 38.64B | 6.51B | 1.29B | 1.37B | 3.82 |
|
IQV
Iqvia Holdings Inc
|
201.43 | 36.52B | 15.32B | 1.41B | 1.96B | 5.95 |
|
IDXX
Idexx Laboratories Inc
|
421.76 | 34.55B | 3.84B | 866.24M | 792.60M | 9.80 |
VolitionRX Ltd Stock (VNRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-02-01 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2022-02-17 | 재개 | Cantor Fitzgerald | Overweight |
| 2021-03-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-05-16 | 개시 | Maxim Group | Buy |
| 2018-05-14 | 재확인 | The Benchmark Company | Buy |
| 2016-09-07 | 재확인 | Rodman & Renshaw | Buy |
| 2016-02-01 | 개시 | Rodman & Renshaw | Buy |
모두보기
VolitionRX Ltd 주식(VNRX)의 최신 뉴스
Benchmark Reaffirms Hold Rating for VolitionRx (NYSE:VNRX) - MarketBeat
VolitionRx (NYSE:VNRX) Coverage Initiated at StockNews.com - Defense World
VolitionRx Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
VolitionRx Limited (AMEX:VNRX) Q3 2024 Earnings Call Transcript - Insider Monkey
VolitionRX: Q3 Earnings Snapshot - New Haven Register
VolitionRX Ltd (VNRX) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... - Yahoo Finance
VolitionRx Posts Strong Q3 Growth and Strategic Advances - TipRanks
Lagoda Investment Management's Strategic Acquisition in Volition - GuruFocus.com
Armistice Capital, LLC Acquires New Stake in VolitionRX Ltd - GuruFocus.com
VolitionRX Ltd Reports Q3 Revenue of $475,000, Missing Estimates of $0.65 Million - GuruFocus.com
VolitionRX Ltd (VNRX) Q3 2024 Earnings Report Preview: What to L - GuruFocus.com
StockNews.com Begins Coverage on VolitionRx (NYSE:VNRX) - MarketBeat
VolitionRx Limited Schedules Third Quarter 2024 Earnings Conference Call and Business Update - Yahoo Finance
Volition Appoints Timothy I. Still as Chairman – Company Announcement - Financial Times
VolitionRx (NYSE:VNRX) Now Covered by StockNews.com - Defense World
Abionic’s test enters increasingly competitive sepsis fray - BioWorld Online
VolitionRx (NYSE:VNRX) Now Covered by Analysts at StockNews.com - Defense World
Volition to share new 'NETs in sepsis management' data insights at upcoming webinar - Quantisnow
VolitionRx adds Dr. Ethel Rubin to its board By Investing.com - Investing.com South Africa
VolitionRx adds Dr. Ethel Rubin to its board - Investing.com India
Volition Appoints Dr. Ethel Rubin as an Independent Director - Quantisnow
Volition Appoints Dr. Ethel Rubin as an Independent Director – Company Announcement - Financial Times
VolitionRx announces executive employment updates - Investing.com India
Agency News | ⚡Tamil Nadu’s Veterinary Varsity Directed by High Court To Consider Transgender Student’s Application - LatestLY
Madras HC directs TN veterinary varsity to not reject transgender's application over identity - Hindustan Times
Madras High Court Orders TN Veterinary University to Accept Transgender Candidate's Application - Law Trend
Don't reject transgender's application over identity HC tells TN veterinary varsity - The Week
Madras High Court Upholds Transgender Rights for Veterinary Course Admissions - Devdiscourse
Volato Facing Class-action WARN Act Lawsuit - Aviation International News
VolitionRx offers oncology assets for licensing - Investing.com India
VolitionRx offers oncology assets for licensing By Investing.com - Investing.com Australia
Volition Announces Board of Directors - TechBuzz News
CRYPTOPSY's New Shirts Are Very Serious - Metal Injection
Terminated Volato Employees File Class Action Lawsuit - FLYING
LifeLabs workers in GTA poised to strike if deal not reached by Saturday - CP24
Investing in VolitionRX Ltd (VNRX): What You Must Know - Knox Daily
Volition Hosts KOL Roundtable on Sepsis - Yahoo Finance
VolitionRX Ltd [VNRX] Records 200-Day SMA of $0.7821 - Knox Daily
The Potential Rise in the Price of VolitionRX Ltd (VNRX) following insiders activity - Knox Daily
VNRX: Nu.Q Vet Test is now available in 17 countries. Cost cutting continues in a plan to be cash flow neutral in 2025. Management focused on signing licensing deals for Capture-PCR (human cancer detection method) and Nu.Q NET for sepsis. $7.0 million fi - Yahoo Finance
Understanding the Risks of Investing in VolitionRX Ltd (VNRX) - Knox Daily
Comparing OncoCyte (NASDAQ:OCX) & VolitionRx (NYSE:VNRX) - Defense World
VolitionRx (NYSEAMERICAN:VNRX) Stock Price Passes Above 50-Day Moving Average of $0.00 - Defense World
VolitionRx Limited (NYSE:VNRX) Director Guy Archibald Innes Purchases 150,000 Shares - Defense World
VolitionRX Ltd (VNRX) Q2 2024 Earnings Call Transcript Highlight - GuruFocus.com
Benchmark Reiterates Hold Rating for VolitionRx (NYSE:VNRX) - Defense World
VolitionRx Limited (AMEX:VNRX) Q2 2024 Earnings Call Transcript - Insider Monkey
Earnings call: VolitionRx reports strong growth and optimistic outlook - Investing.com
VolitionRX: Q2 Earnings Snapshot - San Antonio Express-News
VolitionRX Ltd (VNRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.43%
0.41%
자본화:
|
볼륨(24시간):